Cortexyme, Inc. (NASDAQ:CRTX) Insider Epiq Capital Group, Llc Buys 4,965 Shares

Cortexyme, Inc. (NASDAQ:CRTX) insider Epiq Capital Group, Llc acquired 4,965 shares of Cortexyme stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average cost of $25.35 per share, with a total value of $125,862.75. The purchase was disclosed in a filing with the SEC, which is available at this link.

Epiq Capital Group, Llc also recently made the following trade(s):

  • On Monday, August 19th, Epiq Capital Group, Llc acquired 2,800 shares of Cortexyme stock. The shares were purchased at an average cost of $26.46 per share, with a total value of $74,088.00.

CRTX stock traded down $0.44 during midday trading on Thursday, reaching $24.51. The company had a trading volume of 220 shares, compared to its average volume of 59,404. Cortexyme, Inc. has a 1 year low of $19.50 and a 1 year high of $47.50. The company’s 50-day moving average is $35.10.



Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new position in Cortexyme in the 2nd quarter worth approximately $78,000. Wells Fargo & Company MN purchased a new position in Cortexyme in the 2nd quarter worth approximately $191,000. Bank of New York Mellon Corp purchased a new position in Cortexyme in the 2nd quarter worth approximately $349,000. Landscape Capital Management L.L.C. purchased a new position in Cortexyme in the 2nd quarter worth approximately $535,000. Finally, Northern Trust Corp purchased a new position in Cortexyme in the 2nd quarter worth approximately $991,000. 1.17% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently commented on the stock. Bank of America assumed coverage on shares of Cortexyme in a research note on Monday, June 3rd. They set a “neutral” rating and a $28.00 price objective for the company. Zacks Investment Research raised shares of Cortexyme from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, August 14th. Canaccord Genuity assumed coverage on shares of Cortexyme in a research note on Monday, June 3rd. They set a “buy” rating and a $42.00 price objective for the company. JMP Securities assumed coverage on shares of Cortexyme in a research note on Monday, June 3rd. They set a “mkt outperform” rating and a $53.00 price objective for the company. Finally, Credit Suisse Group assumed coverage on shares of Cortexyme in a research note on Monday, June 3rd. They set an “underperform” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $34.00.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

See Also: Does the discount rate affect the economy?

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.